Business
Zymeworks Outlines Strategic Priorities and Outlook for 2026
Positive Phase 3 HERIZON-GEA-01 results for Ziihera® (zanidatamab-hrii) in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) presented at ASCO GI Up to $440.0 million in milestone payments eligible to be earned related to regulatory approvals of Ziihera in GEA in the United States, Europe, Japan, and ChinaCompany well-positioned to execute new strategy compounding long-term value by integrating royalty growth, strategic acquisitions, and continued internal R&D innovation$125
About this update from Zymeworks Inc.
[{"type":"image","alt":"Zymeworks Inc.","displaySize":"","headline":null,"caption":"Zymeworks Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":107,"url":"https://media.zenfs.com/en/globenewswire.com/f2ce7b52208d3197a799cb87a13ae11f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1Mr3NL5l3JfRng99mnVVlQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/f2ce7b52208d3197a799cb87a13ae11f","width":300,"height":107}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Positive Phase 3 HERIZON-GEA-01 results for Ziihera® (zanidatamab-hrii) in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) presented at ASCO GI ","length":171,"tagName":"p"}]},{"val":[{"type":"text","content":"Up to $440.0 million in milestone payments eligible to be earned related to regulatory approvals of Ziihera in GEA in the United States, Europe, Japan, and China","length":161,"tagName":"p"}]},{"val":[{"type":"text","content":"Company well-positioned to execute new strategy compounding long-term value by integrating royalty growth, strategic acquisitions, and continued internal R&D innovation","length":172,"tagName":"p"}]},{"val":[{"type":"text","content":"$125.0 million share repurchase plan announced in November 2025 available to reduce share count","length":95,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash, cash equivalents, and marketable securities of approximately $270.6 million (unaudited) as of December 31, 2025, combined with anticipated regulatory milestone payments related to potential approvals of Ziihera in GEA, expected to provide cash runway beyond 2028","length":268,"tagName":"p"}]},{"val":[{"type":"text","content":"Company to present at the J.P. Morgan Annual Healthcare Conference on Wednesday, January 14, 2026 at 3:00 pm Pacific Time (PT) ","length":126,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":993,"olType":false},{"type":"text","content":"VANCOUVER, British Columbia, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today outlined its strategic priorities and key milestones for 2026. Following a year of significant clinical, operational...